



LKT Laboratories, Inc.

AZD-8931

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A9813

CAS No. 848942-61-0

Chemical Name 2-[4-({4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}oxy)-1-piperidiny]-N-methylacetamide

Synonym AZD8931, Sapitinib

Formula C₂₃H₂₅ClFN₅O₃

Formula Wt. 473.93

Melting Point


Purity ≥98%

Solubility DMSO 40 mg/mL
Water Insoluble
Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Description AZD-8931 is an inhibitor of EGFR, HER2, and HER3 that exhibits anticancer chemotherapeutic activity. In vitro and in vivo, AZD-8931 suppresses growth of inflammatory breast cancer cells and tumors and induces apoptosis. This compound also inhibits growth in cellular models of non-small cell lung cancer (NSCLC) and squamous cell carcinoma.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A9813	1 mg	\$75.00
A9813	5 mg	\$150.00
A9813	10 mg	\$245.00
A9813	25 mg	\$545.00

References Mu Z, Klinowska T, Dong X, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. *J Exp Clin Cancer Res.* 2014 May 30;33:47. PMID: 24886365.

Tjulandin S, Moiseyenko V, Semiglazov V, et al. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. *Invest New Drugs.* 2014 Feb;32(1):145-53. PMID: 23589215.

Hickinson DM, Klinowska T, Speake G, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. *Clin Cancer Res.* 2010 Feb 15;16(4):1159-69. PMID: 20145185.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.